Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4

British Journal of Pharmacology

Volumn 173, Issue 5, 2016, Pages 856-869

  Wang, X ^a,b   Zhang, Y ^c   Peng, Y ^c   Hutchinson, M R ^d   Rice, K C ^e   Yin, H ^c   Watkins, L R ^c  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; NALOXONE; NALTREXONE; NITRIC OXIDE; OPIATE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; LIPOPOLYSACCHARIDE; NARCOTIC ANTAGONIST; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BIOEQUIVALENCE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; IN VITRO STUDY; ISOMER; MALE; MICROGLIA; MICROGLIAL CELL CULTURE; MOUSE; NEWBORN; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL LINE; DRUG EFFECTS; METABOLISM; PHAGOCYTOSIS; SPRAGUE DAWLEY RAT;

ANIMALS; CELL LINE; CELLS, CULTURED; INTERFERON-BETA; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICROGLIA; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NITRIC OXIDE; PHAGOCYTOSIS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958764748     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13394     Document Type: Article

References (58)

1. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979-6023.
2. Bevan DE, Martinko AJ, Loram LC, Stahl JA, Taylor FR, Joshee S, et al,. (2010). Selection, preparation, and evaluation of small-molecule inhibitors of toll-like receptor 4. ACS Med Chem Lett 1: 194-198.
3. Block ML, Zecca L, Hong JS, (2007). Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
4. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT, (2012). Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci Signal 5: Ra13.
5. Bozza S, Campo S, Arseni B, Inforzato A, Ragnar L, Bottazzi B, et al,. (2014). PTX3 binds MD-2 and promotes TRIF-dependent immune protection in aspergillosis. J Immunol 193: 2340-2348.
6. Chou TC, (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
7. Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, Ways JP, et al,. (1994). NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol 153: 712-723.
8. Coller JK, Hutchinson MR, (2012). Implications of central immune signaling caused by drugs of abuse: Mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Ther 134: 219-245.
9. De Castro C, Parrilli M, Holst O, Molinaro A, (2010). Microbe-associated molecular patterns in innate immunity: Extraction and chemical analysis of gram-negative bacterial lipopolysaccharides. Methods Enzymol 480: 89-115.
10. Dilger RN, Johnson RW, (2008). Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol 84: 932-939.
11. Diogenes A, Ferraz CC, Akopian AN, Henry MA, Hargreaves KM, (2011). LPS sensitizes TRPV1 via activation of TLR4 in trigeminal sensory neurons. J Dent Res 90: 759-764.
12. Falvo JV, Tsytsykova AV, Goldfeld AE, (2010). Transcriptional control of the TNF gene. Curr Dir Autoimmun 11: 27-60.
13. Goodridge HS, McGuiness S, Houston KM, Egan CA, Al-Riyami L, Alcocer MJ, et al,. (2007). Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells. Parasite Immunol 29: 127-137.
14. Grace PM, Hutchinson MR, Maier SF, Watkins LR, (2014). Pathological pain and the neuroimmune interface. Nat Rev Immunol 14: 217-231.
15. Gwak YS, Hassler SE, Hulsebosch CE, (2013). Reactive oxygen species contribute to neuropathic pain and locomotor dysfunction via activation of CamKII in remote segments following spinal cord contusion injury in rats. Pain 154: 1699-1708.
16. Henn A, Lund S, Hedtjarn M, Schrattenholz A, Porzgen P, Leist M, (2009). The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 26: 83-94.
17. Holguin A, O'Connor KA, Biedenkapp J, Campisi J, Wieseler-Frank J, Milligan ED, et al,. (2004). HIV-1 gp120 stimulates proinflammatory cytokine-mediated pain facilitation via activation of nitric oxide synthase-I (nNOS). Pain 110: 517-530.
18. Hutchinson MR, Northcutt AL, Hiranita T, Wang X, Lewis SS, Thomas J, et al,. (2012). Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci 32: 11187-11200.
19. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR, (2011). Exploring the neuroimmunopharmacology of opioids: An integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 63: 772-810.
20. Hutchinson MR, Watkins LR, (2014). Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology 76 (Pt B): 218-227.
21. Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al,. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 28: 20-29.
22. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al,. (2010). Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24: 83-95.
23. Ji RR, Xu ZZ, Gao YJ, (2014). Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13: 533-548.
24. Joce C, Stahl JA, Shridhar M, Hutchinson MR, Watkins LR, Fedichev PO, et al,. (2010). Application of a novel in silico high-throughput screen to identify selective inhibitors for protein-protein interactions. Bioorg Med Chem Lett 20: 5411-5413.
25. Kovacic P, Cooksy AL, (2005). Unifying mechanism for toxicity and addiction by abused drugs: Electron transfer and reactive oxygen species. Med Hypotheses 64: 357-366.
26. Leung L, Cahill CM, (2010). TNF-alpha and neuropathic pain-a review. J Neuroinflammation 7: 27.
27. Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, et al,. (2012). (+)-Naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. Pain 13: 498-506.
28. Loram LC, Sholar PW, Taylor FR, Wiesler JL, Babb JA, Strand KA, et al,. (2012). Sex and estradiol influence glial pro-inflammatory responses to lipopolysaccharide in rats. Psychoneuroendocrinology 37: 1688-1699.
29. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC, (2007). The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632.
30. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): New requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
31. Neumann H, Wekerle H, (2013). Brain microglia: Watchdogs with pedigree. Nat Neurosci 16: 253-255.
32. Northcutt A, Hutchinson M, Wang X, Baratta MV, Hiranita T, Cochran TA, et al,. (2015). DAT isn't all that: Cocaine reward and reinforcement requires toll like receptor 4 signaling. Mol Psychiatry. doi: 10.1038/mp.2014.177.
33. Okun E, Griffioen KJ, Mattson MP, (2011). Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci 34: 269-281.
34. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SPH, Buneman OP, et al,., NC-IUPHAR(2014). The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
35. Pillarisetti S, (2011). Targeting interleukin-1beta for pain. CNS Neurol Disord Drug Targets 10: 571-575.
36. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al,. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282: 2085-2088.
37. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE, (2009). CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 29: 11982-11992.
38. Roman J, Ritzenthaler JD, Fenton MJ, Roser S, Schuyler W, (2000). Transcriptional regulation of the human interleukin 1beta gene by fibronectin: Role of protein kinase C and activator protein 1 (AP-1). Cytokine 12: 1581-1596.
39. Schmidtko A, Tegeder I, Geisslinger G, (2009). No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci 32: 339-346.
40. Stevens CW, Aravind S, Das S, Davis RL, (2013). Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. Br J Pharmacol 168: 1421-1429.
41. Sziebert L, Thomson PD, Jinkins J, Rice K, Adams T Jr, Henriksen N, et al,. (1983). Effect of naloxone treatment on the cardiopulmonary response to endotoxin in sheep. Adv Shock Res 10: 121-128.
42. Takeuchi O, Akira S, (2010). Pattern recognition receptors and inflammation. Cell 140: 805-820.
43. Tayfun Uzbay I, Oglesby MW, (2001). Nitric oxide and substance dependence. Neurosci Biobehav Rev 25: 43-52.
44. Theberge FR, Li X, Kambhampati S, Pickens CL, St Laurent R, Bossert JM, et al,. (2013). Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biol Psychiatry 73: 729-737.
45. Toda N, Kishioka S, Hatano Y, Toda H, (2009). Modulation of opioid actions by nitric oxide signaling. Anesthesiology 110: 166-181.
46. Tse KH, Chow KB, Leung WK, Wong YH, Wise H, (2014). Lipopolysaccharide differentially modulates expression of cytokines and cyclooxygenases in dorsal root ganglion cells via toll-like receptor-4 dependent pathways. Neuroscience 267: 241-251.
47. Wang HY, Burns LH, (2009). Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One 4: E4282.
48. Wang Q, Zhou H, Gao H, Chen SH, Chu CH, Wilson B, et al,. (2012a). Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase. J Neuroinflammation 9: 32.
49. Wang X, Grace PM, Pham MN, Cheng K, Strand KA, Smith C, et al,. (2013a). Rifampin inhibits toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain. FASEB J 27: 2713-2722.
50. Wang X, Loram LC, Ramos K, de Jesus AJ, Thomas J, Cheng K, et al,. (2012b). Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci U S A 109: 6325-6330.
51. Wang X, Smith C, Yin H, (2013b). Targeting toll-like receptors with small molecule agents. Chem Soc Rev 42: 4859-4866.
52. Watkins LR, Wang X, Mustafa S, Hutchinson MR, (2014). In vivo veritas: (+)-naltrexone's actions define translational importance: A letter in response to Skolnick et al. 'translational potential of naloxone and naltrexone as TLR4 antagonists'. Trends Pharmacol Sci 35: 432-433.
53. Wu HE, Sun HS, Cheng CW, Terashvili M, Tseng LF, (2006). dextro-Naloxone or levo-naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non-opioid mechanism. Eur J Neurosci 24: 2575-2580.
54. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, et al,. (2010). A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 107: 11942-11947.
55. Yowtak J, Lee KY, Kim HY, Wang J, Kim HK, Chung K, et al,. (2011). Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. Pain 152: 844-852.
56. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, et al,. (2014). an rna-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34: 11929-11947.
57. Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vasquez-Vivar J, et al,. (2003). Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: Potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med 34: 1359-1368.
58. Zhao XJ, Dong Q, Bindas J, Piganelli JD, Magill A, Reiser J, et al,. (2008). TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol. J Immunol 181: 3049-3056.